This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. . """""""" Glyceollins as novel targeted therapeutics for the treatment of metastatic triple negative breast cancer."""""""" Dr. Collins-Burow obtained her Ph.D. from Tulane in 1998. She then went to medical school at Tulane and carried out her residency and fellowship in hematology/oncology at Tulane as well. Although she stayed in touch with the laboratory somewhat and carried on some research, she needs time to get her laboratory work going again. Thus, we decided that she would be an alternate rather than a PJI and would receive pilot funding from the Cancer Center to begin to establish her model systems. Her outstanding fit in terms of animal models of carcinogenesis, as well as cell survival would make her an outstanding replacement for a graduating PJI when her work will be able to take off. Dr. Collins-Burow has demonstrated in the MDA-MB-231 cell line that glyceollin inhibits proliferation/survival of these cells in clonogenicity assays. Utilizing an in vivo xenograft mouse model she has shown the ability of glyceollin to suppress tumor growth of the MDA-MB-231 cells. A very exciting finding on follow-up of this study was a decrease in visceral lung metastasis in the animals treated with glyceollin. Based upon these preliminary data she proposes to test the overall hypothesis that glyceollins function as a novel targeted agent in triple negative breast cancer suppressing tumorigenesis and metastasis. She propose the following specific aims:
Specific Aim #1, To test the hypothesis that glyceollins block triple negative breast cancer migration/invasion and chemokine signaling in vitro.
Specific Aim #2, To test the hypothesis that glyceollin regulates key clusters of gene expression associated with a metastatic phenotype and chemokine function in triple negative breast cancer cells.
Specific Aim #3, To test the hypothesis that glyceollins suppress in vivo tumorigenesis and metastasis of triple negative breast cancer cells. We believe that the glyceollins represent the parent structure for a new class of anti-cancer agents that can target tumorigenesis and metastasis of triple negative breast cancer while enabling us to begin to elucidate the distinct molecular targets of this disease which will ultimately be translated to a clinical trial for triple negative breast cancer.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
Exploratory Grants (P20)
Project #
Application #
Study Section
Special Emphasis Panel (ZRR1-RI-B (01))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Tulane University
Public Health & Prev Medicine
Schools of Public Health
New Orleans
United States
Zip Code
Wu, Victor J; Pang, Darren; Tang, Wendell W et al. (2017) Obesity, age, ethnicity, and clinical features of prostate cancer patients. Am J Clin Exp Urol 5:1-9
Zhang, Q; Liu, S; Parajuli, K R et al. (2017) Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene 36:687-699
Gopalakrishnan, Anusha M; Aly, Ahmed S I; Aravind, L et al. (2017) Multifunctional Involvement of a C2H2 Zinc Finger Protein (PbZfp) in Malaria Transmission, Histone Modification, and Susceptibility to DNA Damage Response. MBio 8:
Liu, Yao-Zhong; Zhang, Lei; Roy-Engel, Astrid M et al. (2017) Carcinogenic effects of oil dispersants: A KEGG pathway-based RNA-seq study of human airway epithelial cells. Gene 602:16-23
Yang, Lingyun; Huang, Feng; Mei, Jiandong et al. (2017) Posttranscriptional Control of PD-L1 Expression by 17?-Estradiol via PI3K/Akt Signaling Pathway in ER?-Positive Cancer Cell Lines. Int J Gynecol Cancer 27:196-205
Wang, Xun; Yang, Lingyun; Huang, Feng et al. (2017) Inflammatory cytokines IL-17 and TNF-? up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett 184:7-14
Ma, Lin; Li, Jingwu; Nie, Qiang et al. (2017) Organoid culture of human prostate cancer cell lines LNCaP and C4-2B. Am J Clin Exp Urol 5:25-33
Servant, Geraldine; Streva, Vincent A; Derbes, Rebecca S et al. (2017) The Nucleotide Excision Repair Pathway Limits L1 Retrotransposition. Genetics 205:139-153
Martin, Elizabeth C; Conger, Adrienne K; Yan, Thomas J et al. (2017) MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. FEBS Lett 591:382-392
Zhang, Qiuyang; Liu, Sen; Ge, Dongxia et al. (2017) Targeting Th17-IL-17 Pathway in Prevention of Micro-Invasive Prostate Cancer in a Mouse Model. Prostate 77:888-899

Showing the most recent 10 out of 154 publications